Search results for "Adverse effect"

showing 10 items of 1065 documents

The use of topical corticoids in oral pathology

2009

This review examines the most important aspects of the use of topical corticosteroids in oral pathology. We provide a detailed analysis of the most common types of corticosteroids used, their methods of application and the clinical data that must be managed in order to monitor the effectiveness of the treatment. We also analyze the correctable causes of treatment failure and the possible adverse effects that may occur after applying these drugs. All of this is achieved by conducting a critical review of these concepts.

medicine.medical_specialtyPathologybusiness.industryAdrenal cortex hormonesAdministration TopicalMouth Mucosamedicine.disease:CIENCIAS MÉDICAS [UNESCO]Treatment failureOtorhinolaryngologyAdrenal Cortex HormonesUNESCO::CIENCIAS MÉDICASOral and maxillofacial pathologyMedicineHumansSurgerybusinessAdverse effectIntensive care medicineMouth mucosaMouth DiseasesGeneral Dentistry
researchProduct

The dilemma for patients with chronic hepatitis C: treat now or warehouse?

2013

Dual therapy with peginterferon and ribavirin, the only treatent for chronic hepatitis C available In Italy and in many other ountries worldwide up to 2013, obtains satisfactory response ates in infections with hepatitis C virus (HCV) genotype 2, but far rom optimal for other genotypes [1,2]. Eradication requires 6–12 onths of therapy, with significant inconvenience for patients: dverse reactions force premature termination in about 20% of atients and reduced the quality of life for almost all who persist n treatment. In view of the important and prolonged side effects, nterferon-based treatment is perceived as a nightmare by many symptomatic,well-being, socially activepatients (the largema…

medicine.medical_specialtyPediatricsTime FactorsProlineHepatitis C virusAlpha interferonmedicine.disease_causeAntiviral AgentsTelaprevirPolyethylene Glycolschemistry.chemical_compoundLiver diseaseBoceprevirDrug DiscoveryRibavirinmedicineHumansProtease InhibitorsAdverse effectWatchful WaitingDrug CarriersHepatologybusiness.industryRibavirinGastroenterologyInterferon-alphaHepatitis C Chronicmedicine.diseaseSurgeryEastern europeanchemistryHCVDrug Therapy CombinationbusinessOligopeptidesmedicine.drugDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

EPA-0666 – Long-term maintenance of efficacy of extended-release guanfacine hydrochloride (GXR) in children and adolescents with attention-deficit/hy…

2014

Introduction GXR, a selective α2A-adrenergic agonist, is a non-stimulant ADHD treatment approved in the USA for children and adolescents, and in Canada for children. Objectives To evaluate long-term maintenance of efficacy of GXR in children and adolescents with ADHD who respond to an initial open-label, short-term trial. Aims To determine if there is a higher rate of treatment failure for placebo vs GXR during the double-blind randomised-withdrawal phase (RWP) (NCT01081145). Methods Patients (6–17 years) meeting DSM-IV-TR criteria for ADHD, baseline ADHD Rating Scale-IV (ADHD-RS-IV) ≥32 and Clinical Global Impressions-Severity (CGI-S) ratings ≥4 were enrolled. Following 7-week dose optimiz…

medicine.medical_specialtyPediatricsbusiness.industryVital signsLong term maintenancemedicine.diseasePlaceboDouble blindPsychiatry and Mental healthmental disordersPhysical therapymedicineClinical endpointAttention deficit hyperactivity disorderGuanfacine HydrochlorideAdverse effectbusinessEuropean Psychiatry
researchProduct

Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society

2011

Three years after the introduction of natalizumab (NA) therapy for the second line treatment of relapsing-remitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficacious in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.

medicine.medical_specialtyPediatricspml; iris; multiple sclerosis; natalizumabMultiple SclerosisNeurologypmlMEDLINEProgressive MultifocalDermatologyRelapsing-RemittingAntibodies Monoclonal HumanizedAntibodiesLeukoencephalopathyMultiple Sclerosis Relapsing-RemittingNatalizumabLeukoencephalopathyMonoclonalmedicineHumansAdverse effectAntibodies; Monoclonal; Humanized Antibodies; therapeutic use Humans Leukoencephalopathy; Progressive Multifocal; chemically induced Multiple Sclerosis; Relapsing-Remitting; drug therapyHumanizedMultiple sclerosis Natalizumab PML IRISirisbusiness.industryNatalizumabProgressive multifocal leukoencephalopathyMultiple sclerosisLeukoencephalopathy Progressive MultifocalAntibodies MonoclonalGeneral Medicinemedicine.diseasedrug therapyPsychiatry and Mental healththerapeutic usechemically inducednatalizumab multiple sclerosis treatment guidelinesPhysical therapySettore MED/26 - NeurologiaNeurology (clinical)Neurosurgerybusinessmedicine.drug
researchProduct

Pharmacokinetic and clinical evaluation of esomeprazole and ASA for the prevention of gastroduodenal ulcers in cardiovascular patients.

2012

Low-dose aspirin (ASA, 75 - 325 mg/day) is widely used for the primary and secondary prevention of cardiovascular (CV) diseases. However, the value of primary prevention ASA is uncertain as the reduction in occlusive events needs to be weighed against the significant increase in major bleedings. Prevention with antisecretory drugs has been proposed to reduce the incidence of ASA-induced gastrointestinal (GI) bleedings, but non-adherence to gastro-protection is of concern, as it significantly increases the risk of upper GI adverse events. Beside patients and physicians education, one approach to overcome non-adherence is the development of fixed-dose combination.This review explores the resu…

medicine.medical_specialtyPeptic UlcerToxicologyGastroenterologyEsomeprazolePharmacokineticsInternal medicinemedicineHumansIn patientDrug InteractionsAdverse effectRandomized Controlled Trials as TopicPharmacologyAspirinAspirinbusiness.industryIncidence (epidemiology)EsomeprazoleGeneral MedicineAnti-Ulcer Agentsdigestive system diseasesGastroduodenal ulcerCardiovascular DiseasesbusinessClinical evaluationPlatelet Aggregation Inhibitorsmedicine.drugExpert opinion on drug metabolismtoxicology
researchProduct

Efficacy of DiscoGel in Treatment of Degenerative Disc Disease: A Prospective 1-Year Observation of 67 Patients

2021

Patients with degenerative disc disease may suffer from chronic lumbar discogenic (DP) or radicular leg (RLP) pain. Minimally invasive DiscoGel therapy involves the percutaneous injection of an ethanol gel into the degenerated disk’s nucleus pulposus. This paper compares the 1-year outcome of such treatment in DP and RLP patients. We operated on 67 patients (49 men and 18 women) aged 20–68 years (mean age 46 ± 11 years) with DP (n = 45) and RLP (n = 22), of at least 6–8 weeks duration, with no adverse effects. We evaluated the treatment outcome with Core Outcome Measures Index (COMI) and Visual Analog Scale (VAS). A year after the ethanol gel injection, in the DP cohort, COMI and VAS droppe…

medicine.medical_specialtyPercutaneousVisual analogue scaleNeurosciences. Biological psychiatry. NeuropsychiatryArticleDegenerative disc diseaseLumbarMedicineethanol gelAdverse effectradiculopathylow back painpercutaneous spine surgeryCore (anatomy)business.industryGeneral Neurosciencediscogenic painchemonucleolysis; discogenic pain; ethanol gel; low back pain; percutaneous spine surgery; radiculopathymedicine.diseaseLow back painSurgerychemonucleolysisCohortmedicine.symptombusinessRC321-571Brain Sciences
researchProduct

TCT-282 Risk Factors Associated with Adverse Events during Chronic Total Occlusion Percutaneous Coronary Interventions: A sub-Analysis of the OPEN-CT…

2016

Coronary chronic total occlusions (CTOs) are prevalent and the development of the hybrid approach to CTO PCI has been associated with increased technical success rates. However, the incidence and predictors of adverse events (AEs) during CTO PCI remains poorly defined. We analyzed baseline patient

medicine.medical_specialtyPercutaneousbusiness.industryIncidence (epidemiology)Technical successPsychological intervention030204 cardiovascular system & hematologyHybrid approachTotal occlusion03 medical and health sciencessurgical procedures operative0302 clinical medicineInternal medicineConventional PCImedicineCardiologycardiovascular diseases030212 general & internal medicineCardiology and Cardiovascular MedicineAdverse effectbusinessJournal of the American College of Cardiology
researchProduct

The percutaneous treatment of Patent Foramen Ovale, an effective and safe therapeutic choice

2013

Introduction: The aim of our study is to evaluate the feasibility, safety and efficacy of the percutaneous closure of PFO (abnormal communication between the right and left atrium). Methods: Between July 2009 and October 2012 percutaneous closure was performed in 37 patients. The presence of PFO was diagnosed through the use of ultrasound techniques: transcranial doppler with contrast (cTCD), transthoracic echocardiography(TTE) and transesophageal echocardiography (TEE). Follow-up was composed consisted of a Holter ECG 7 days after the closure with a 24 hour heart rhythm monitoring, to evaluate eventual arrhythmia cases and programmed controls which included a TTE at 1-3 months, TTE+ cTCD a…

medicine.medical_specialtyPercutaneousbusiness.industryMedicine (all)patent foramen ovaleRGeneral Medicinemedicine.diseaseNew onset atrial fibrillationTranscranial DopplerSurgeryUltrasound techniquespercutaneous closuremedicine.anatomical_structurePfo closureInternal medicinemedicineCardiologyPatent foramen ovalecryptogenic strokeMedicineAdverse effectbusinessInteratrial septumOpen Medicine
researchProduct

Percutaneous Femoropopliteal Bypass: 2-Year Results of the DETOUR System

2021

Purpose: This study investigated the 2-year safety and effectiveness of the PQ Bypass DETOUR system as a percutaneous femoropopliteal bypass. Materials and Methods: Seventy-eight patients with 82 long-segment femoropopliteal lesions were enrolled in this prospective, single-arm, multicenter study. The DETOUR system deployed Torus stent grafts directed through a transvenous route. Eligible patients included those with lesions of >10 cm and average of 371±55 mm. Key safety endpoints included major adverse events (MAEs) and symptomatic deep venous thrombosis in the target limb. Effectiveness endpoints included primary patency defined as freedom from ≥50% stenosis, occlusion, or clinically-d…

medicine.medical_specialtyPercutaneousmedicine.medical_treatmentLesionPeripheral Arterial DiseaseOcclusionmedicineHumansPopliteal ArteryRadiology Nuclear Medicine and imagingProspective StudiesAdverse effectVascular Patencybusiness.industryEndovascular ProceduresStentmedicine.diseaseSurgeryFemoral ArteryVenous thrombosisStenosisTreatment OutcomeStentsSurgerymedicine.symptomCardiology and Cardiovascular MedicinebusinessClaudicationJournal of Endovascular Therapy
researchProduct

Cytoreductive surgery and mitomycin C hyperthermic intraperitoneal chemotherapy with CO2 recirculation (HIPEC-CO2) for colorectal cancer peritoneal m…

2021

Peritoneal dissemination from colorectal cancer (CRC) has long been associated with unfavorable prognosis. However, in the last decades, the combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) was able to obtain up to 30% 5-year survival rate in selected centers. Despite the wide diffusion of CRS and HIPEC, until now, there are no clear recommendations on the drug of choice for HIPEC nor its technique, and safety and efficacy data of HIPEC regimens and techniques are lacking. We performed a retrospective analysis of a prospectively maintained database of 26 CRS and mitomycin C HIPEC with CO2 recirculation (HIPEC-CO2) for CRC peritoneal metastasis…

medicine.medical_specialtyPeritoneal metastasisColorectal cancerMitomycinSettore MED/18 - CHIRURGIA GENERALE2Hyperthermic Intraperitoneal Chemotherapy030230 surgery03 medical and health sciences0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansHyperthermiaAdverse effectSurvival ratePeritoneal NeoplasmsRetrospective StudiesCarcinomatosisHIPECbusiness.industryInducedMitomycin CCommon Terminology Criteria for Adverse EventsCytoreduction Surgical ProceduresHyperthermia InducedCarbon DioxidePrognosismedicine.diseaseColorectal cancerCombined Modality TherapyHIPEC-COSurgerySurvival Rate030220 oncology & carcinogenesisPeritoneal metastasisSurgeryHyperthermic intraperitoneal chemotherapyColorectal NeoplasmsbusinessCytoreductive surgeryUpdates in Surgery
researchProduct